Page History
Session Summary
The use of i2b2 for determining feasibility of clinical studies and clinical trials, focusing on the use of i2b2 in networks across the country, and novel approaches to allowing investigators to perform feasibility studies using i2b2-based client tools.
Douglas MacFadden
Chief Informatics Officer
Harvard Catalyst
| html-text |
|---|
<html>
<body>
<p class="i2b2-event-presenter-position">Chief Informatics Officer</p>
<p class="i2b2-event-presenter-company">Harvard Catalyst</p>
</body>
</html> |
P1: SHRINE Update
- Review of all the new features added to the SHRINE Software
| Button | ||||
|---|---|---|---|---|
|
Nich Wattanasin, MS
Corporate Team Lead
Partners HealthCare
| html-text |
|---|
<html>
<body>
<p class="i2b2-event-presenter-position">Corporate Team Lead</p>
<p class="i2b2-event-presenter-company">Partners HealthCare</p>
</body>
</html> |
P2: Feasibility Studies Using SHRINE and i2b2
for Feasibility Studies- New features added to SHRINE and i2b2 Web Clients to help improve the workflow of identifying and extracting patient sets for clinical studies or trials.
| Button | ||
|---|---|---|
|
|
profile-picture
User
Jack London, MD
P3:
Kavi Wagholikar, PhD
Assistant in Computer Science
Massachusetts General Hospital
| html-text |
|---|
<html>
<body>
<p class="i2b2-event-presenter-position">Assistant in Computer Science</p>
<p class="i2b2-event-presenter-company">Massachusetts General Hospital</p>
</body>
</html> |
P4: SMART on FHIR on i2b2
- Review of new FHIR cell
- Standardizing docker containers
| Button | ||||
|---|---|---|---|---|
|
